AlloVir, Inc. (NASDAQ:ALVR – Get Free Report)’s share price dropped 4.4% during mid-day trading on Thursday . The stock traded as low as $3.45 and last traded at $3.47. 82,984 shares changed hands during trading, an increase of 429% from the average session volume of 15,685 shares. The stock had previously closed at $3.63.
AlloVir Price Performance
The business has a fifty day moving average of $4.10 and a 200 day moving average of $5.45. The stock has a market cap of $17.50 million, a price-to-earnings ratio of -0.17 and a beta of 0.63.
AlloVir Company Profile
AlloVir, Inc is a clinical-stage biopharmaceutical company specializing in the development of off-the-shelf, allogeneic virus-specific T-cell immunotherapies for the prevention and treatment of life-threatening viral infections in immunocompromised patients. The company’s proprietary Multi-Virus-Targeting Cell (MTC) platform enables the rapid identification, isolation and expansion of virus-specific T cells from healthy donors, with the aim of offering broad coverage against multiple clinically significant viruses.
AlloVir’s pipeline includes several product candidates designed to address unmet needs in transplant medicine and other immunosuppressed settings.
Further Reading
- Five stocks we like better than AlloVir
- AeroVironment’s Record Backlog and Earnings Beat Fuel Recovery Case
- Corning Just Locked In a Massive Verizon Fiber Deal as AI Infrastructure Expands
- 3 Under-$20 Stocks Tied to the Future of U.S. Energy and Materials
- Uncle Sam’s Quantum Leap: Feds Fund a $300M Quantum Supercycle
Receive News & Ratings for AlloVir Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AlloVir and related companies with MarketBeat.com's FREE daily email newsletter.
